Literature DB >> 26970151

Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.

A M Kelly1, B Smith2, Z Luo3, B Given4, T Wehrwein4, I Master5, J E Farley6.   

Abstract

SETTING: An urban out-patient clinic in Durban, South Africa, providing community-based treatment for drug-resistant tuberculosis (TB).
OBJECTIVE: To describe concordance between patient report and clinician documentation of adverse drug reactions (ADRs) to treatment for multidrug-resistant TB (MDR-TB).
DESIGN: ADRs were documented by interview using an 18-item symptom checklist and medical record data abstraction during a cross-sectional parent study with 121 MDR-TB patients, 75% of whom were co-infected with the human immunodeficiency virus. Concordance was analyzed using Cohen's κ statistic, Gwet's agreement coefficient (AC) 1, and McNemar's test.
RESULTS: ADRs were reported much more frequently in patient interviews (μ = 8.6) than in medical records (μ = 1.4). Insomnia was most common (67% vs. 2%), followed by peripheral neuropathy (65% vs. 18%), and confusion (61 vs. 4%). κ scores were very low, with the highest degree of concordance found in hearing loss (κ = 0.23), which was the only ADR not found to be significantly different between the two data sources (P = 0.34).
CONCLUSIONS: Our study showed a lack of concordance between patient report and clinician documentation of ADRs. These findings indicate the need for improved documentation of ADRs to better reflect patients' experiences during MDR-TB treatment. These data have important implications for country-level pharmacovigilance programs that rely on clinician documentation of ADRs for MDR-TB policy formation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26970151      PMCID: PMC4830122          DOI: 10.5588/ijtld.15.0318

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  29 in total

Review 1.  Systematic review of patient-reported outcome measures in clinical vestibular research.

Authors:  Eric Fong; Carol Li; Rebecca Aslakson; Yuri Agrawal
Journal:  Arch Phys Med Rehabil       Date:  2014-10-08       Impact factor: 3.966

2.  Strengthening pharmacovigilance in South Africa.

Authors:  U Mehta; M Dheda; G Steel; M Blockman; A Ntilivamunda; G Maartens; Y Pillay; K Cohen
Journal:  S Afr Med J       Date:  2014-02

Review 3.  Advancing the science of symptom management.

Authors:  M Dodd; S Janson; N Facione; J Faucett; E S Froelicher; J Humphreys; K Lee; C Miaskowski; K Puntillo; S Rankin; D Taylor
Journal:  J Adv Nurs       Date:  2001-03       Impact factor: 3.187

Review 4.  Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.

Authors:  Shanshan Wu; Yuelun Zhang; Feng Sun; Mingting Chen; Lin Zhou; Ni Wang; Siyan Zhan
Journal:  Am J Ther       Date:  2016 Mar-Apr       Impact factor: 2.688

5.  Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.

Authors:  James C M Brust; N Sarita Shah; Theo L van der Merwe; Sheila Bamber; Yuming Ning; Moonseong Heo; Anthony P Moll; Marian Loveday; Umesh G Lalloo; Gerald H Friedland; Neel R Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

6.  Agreement between patient-reported symptoms and their documentation in the medical record.

Authors:  Serguei V Pakhomov; Steven J Jacobsen; Christopher G Chute; Veronique L Roger
Journal:  Am J Manag Care       Date:  2008-08       Impact factor: 2.229

7.  Depression symptomatology and diagnosis: discordance between patients and physicians in primary care settings.

Authors:  Chizobam Ani; Mohsen Bazargan; David Hindman; Douglas Bell; Muhammad A Farooq; Lutful Akhanjee; Francis Yemofio; Richard Baker; Michael Rodriguez
Journal:  BMC Fam Pract       Date:  2008-01-03       Impact factor: 2.497

8.  Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study.

Authors:  Evans L Sagwa; Aukje K Mantel-Teeuwisse; Nunurai C Ruswa
Journal:  J Pharm Policy Pract       Date:  2014-10-21

Review 9.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

10.  "Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis.

Authors:  Shona Horter; Beverley Stringer; Lucy Reynolds; Muhammad Shoaib; Samuel Kasozi; Esther C Casas; Meggy Verputten; Philipp du Cros
Journal:  BMC Health Serv Res       Date:  2014-02-21       Impact factor: 2.655

View more
  6 in total

1.  Risk factors for poor engagement in drug-resistant TB care in South Africa: a systematic review.

Authors:  K C McNabb; A Bergman; J E Farley
Journal:  Public Health Action       Date:  2021-09-21

2.  Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study.

Authors:  Asif Massud; Syed Azhar Syed Sulaiman; Nafees Ahmad; Muhammad Shafqat; Long Chiau Ming; Amer Hayat Khan
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 3.  Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.

Authors:  H Hong; C Budhathoki; J E Farley
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

4.  Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.

Authors:  Yang Zhang; Shanshan Wu; Yinyin Xia; Ni Wang; Lin Zhou; Jing Wang; Renfei Fang; Feng Sun; Mingting Chen; Siyan Zhan
Journal:  Med Sci Monit       Date:  2017-05-18

5.  "Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.

Authors:  Arjunkumar Jakasania; Kalpita Shringarpure; Dixit Kapadia; Radhika Sharma; Kedar Mehta; Arpit Prajapati; Soundappan Kathirvel
Journal:  BMC Infect Dis       Date:  2020-12-02       Impact factor: 3.090

6.  Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.

Authors:  Paulo Henrique Santos Andrade; Iza Maria Fraga Lobo; Wellington Barros da Silva
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.